Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3

Breast Cancer Research

Volumn 10, Issue 4, 2008, Pages

  Young, Christian D ^a,b   Nolte, Erica C ^a,b   Lewis, Andrew ^a   Serkova, Natalie J ^a   Anderson, Steven M ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB2 PROTEIN, MOUSE; PROTEIN KINASE B;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; CARCINOMA; ENZYME ACTIVATION; EXPERIMENTAL NEOPLASM; HUMAN; METABOLISM; METHODOLOGY; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MAMMARY NEOPLASMS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 65849362115     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2132     Document Type: Article

References (57)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712. 10.1126/science.2470152, 2470152.
3. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115. 10.1016/0092-8674(88)90184-5, 2898299.
4. Guy CT, Cardiff RD, Muller WJ. Activated neu induces rapid tumor progression. Journal of Biological Chemistry 1996, 271:7673-7678. 10.1074/jbc.271.16.9567, 8631805.
5. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989, 57:931-936. 10.1016/0092-8674(89)90331-0, 2567634.
6. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992, 89:10578-10582. 50384, 1359541, 10.1073/pnas.89.22.10578.
7. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO Journal 1999, 18:2149-2164. 1171299, 10205169, 10.1093/emboj/18.8.2149.
8. Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res 2005, 7:R708-R718. 1242139, 16168116, 10.1186/bcr1281.
9. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938. 166416, 12853564, 10.1073/pnas.1537685100.
10. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 1994, 91:8132-8136. 44559, 8058768, 10.1073/pnas.91.17.8132.
11. Schwertfeger KL, Richert MM, Anderson SM. Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol 2001, 15:867-881. 10.1210/me.15.6.867, 11376107.
12. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 2001, 21:2203-2212. 86854, 11238953, 10.1128/MCB.21.6.2203-2212.2001.
13. Ackler S, Ahmad S, Tobias C, Johnson MD, Glazer RI. Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene 2002, 21:198-206. 10.1038/sj.onc.1205052, 11803463.
14. Bellacosa A, Tests JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine threonine kinase containing an SH2-like region. Science 1991, 254:274-277. 10.1126/science.1833819, 1833819.
15. Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Can Res 2004, 64:3171-3178. 15126356, 10.1158/0008-5472.CAN-03-3465.
16. Dourdin N, Schade B, Lesurf R, Hallett M, Munn RJ, Cardiff RD, Muller WJ. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Can Res 2008, 68:2122-2131. 18381417, 10.1158/0008-5472.CAN-07-5727.
17. Muller WJ, Arteaga CL, Muthuswamy SK, Siegel PM, Webster MA, Cardiff RD, Meise KS, Li F, Halter SA, Coffey RJ. Synergistic interaction of the neu proto-oncogene product and transforming growth factor a in the mammary epithelium of transgenic mice. Mol Cell Biol 1996, 16:5726-5736. 231573, 8816486.
18. Siegel PM, Dankort WL, Hardy WR, Muller WJ. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 1994, 14:7068-7077. 359240, 7935422.
19. Rudolph MC, McManaman JL, Phang T, Russel T, Kominsky DM, Serkova N, Anderson SM, Neville MC. Metabolic regulation in the lactating mammary gland: a lipid synthesizing machine. Physiol Genomics 2007, 28:323-336.
20. Andrechek ER, Muller WJ. Tyrosine kinase signalling in breast cancer. Tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res 2000, 2:211-216. 138777, 11250712, 10.1186/bcr56.
21. Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 1999, 253:78-87. 10.1006/excr.1999.4706, 10579913.
22. Siegel PM, Hardy WR, Muller WJ. Mammary gland neoplasia: insights from transgenic mouse models. BioEssays 2000, 22:554-563. 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A, 10842309.
23. Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, Macleod CL, Shyamala G, Gillgrass AE, Cardiff RD. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 2002, 161:1087-1097. 1867237, 12213737.
24. Ishizawar RC, Miyake T, Parsons SJ. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 2007, 26:3503-3510. 10.1038/sj.onc.1210138, 17173075.
25. Xu W, Yuan X, Beebe K, Xiang Z, Neckers L. Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity. Mol Cell Biol 2007, 27:220-228. 1800645, 17030621, 10.1128/MCB.00899-06.
26. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005, 1:2005. 1681463, 16729043, 10.1038/msb4100012.
27. Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001, 21:4265-4275. 87087, 11390655, 10.1128/MCB.21.13.4265-4275.2001.
28. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM, Jones FE. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 2006, 66:6412-6420. 10.1158/0008-5472.CAN-05-2368, 16778220.
29. Olayioye MA, Badache A, Daly JM, Hynes NE. An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway. Exp Cell Res 2001, 267:81-87. 10.1006/excr.2001.5242, 11412040.
30. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ. Mammary tumors expressing the neu proto-oncogene possess elevated c-src tyrosine kinase activity. Mol Cell Biol 1994, 14:735-743. 358422, 7903421.
31. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-src reveal features of its autoinhibitory mechanism. Molecular Cell 1999, 3:629-638. 10.1016/S1097-2765(00)80356-1, 10360179.
32. Mayer BJ. Signal transduction: clamping down on Src activity. Current Biology 1997, 7:R295-R298. 10.1016/S0960-9822(06)00141-2, 9115388.
33. Crouin C, Arnaud M, Gesbert F, Camonis J, Bertoglio J. A yeast two-hybrid study of human p97/Gab2 interactions with its SH2 domain-containing binding partners. FEBS Lett 2001, 495:148-153. 10.1016/S0014-5793(01)02373-0, 11334882.
34. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274. 10.1016/j.cell.2007.06.009, 17604717.
35. Ursini-Siegel J, Hardy WR, Zou D, Lam SHL, Sanguin-Gendreau V, Cardiff RD, Pawson T, Muller WJ. ShcA signaling is essential for tumour progression in mouse models of human breast cancer. EMBO Journal 2008, 27:910-920. 10.1038/emboj.2008.22, 18273058.
36. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310. 10.1038/sj.onc.1210422, 17496923.
37. Anderson NG, Maller JL, Tonks NK, Sturgill TW. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 1990, 343:651-653. 10.1038/343651a0, 2154696.
38. Decaprio JA, Furukawa Y, Ajchenbaum F, Griffin JD, Livingston DM. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci USA 1992, 89:1795-1798. 48539, 1531876, 10.1073/pnas.89.5.1795.
39. Goodrich DW, Wang NP, Qian Y-W, Lee EYHP, Lee W-H. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991, 67:293-302. 10.1016/0092-8674(91)90181-W, 1655277.
40. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes and Dev 2004, 18:2699-2711. 15545627, 10.1101/gad.1256504.
41. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA. Cell cycle control in breast cancer cells. J Cell Biochem 2006, 97:261-274. 10.1002/jcb.20690, 16267837.
42. Hatanaka M. Transport of sugars in tumor cell membranes. Biochim Biophys Acta 1974, 355:77-104.
43. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314. 10.1126/science.123.3191.309, 13298683.
44. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64:3892-3899. 10.1158/0008-5472.CAN-03-2904, 15172999.
45. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003, 23:7315-7328. 230333, 14517300, 10.1128/MCB.23.20.7315-7328.2003.
46. Richert MM, Schwertfeger KL, Ryder JW, Anderson SM. An atlas of mouse mammary gland development. J Mam Gland Bio Neo 2000, 5:227-241. 11149575, 10.1023/A:1026499523505.
47. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO Journal 2000, 19:3159-3167. 313958, 10880430, 10.1093/emboj/19.13.3159.
48. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007, 120:1874-1882. 10.1002/ijc.22423, 17266042.
49. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proceedings of the National Academy of Sciences 2006, 103:1475-1479. 16432179, 1360603, 10.1073/pnas.0510857103.
50. Parsons R, Simpson L. PTEN and cancer. Methods Mol Biol 2003, 222:147-166.
51. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444. 10.1038/nature05933, 17611497.
52. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007, 67:167-177. 10.1158/0008-5472.CAN-06-3782, 17210696.
53. Ju X, Katiyar S, Wang C, Liu M, Jiao X, Li S, Zhou J, Turner J, Lisanti MP, Russell RG, Mueller SC, Ojeifo J, Chen WS, Hay N, Pestell RG. Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci USA 2007, 104:7438-7443. 1863437, 17460049, 10.1073/pnas.0605874104.
54. Young CD, Anderson SM. Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res 2008, 10:202. 2374962, 18304378, 10.1186/bcr1852.
55. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321. 10.1016/j.ccr.2005.09.008, 16226706.
56. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51. 10.1056/NEJMra043186, 17611206.
57. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127. 10.1016/j.ccr.2004.06.022, 15324695.